Nisa Investment Advisors LLC Sells 275,503 Shares of Perrigo Company plc (NYSE:PRGO)

Nisa Investment Advisors LLC lessened its stake in Perrigo Company plc (NYSE:PRGO) by 90.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 29,445 shares of the company’s stock after selling 275,503 shares during the period. Nisa Investment Advisors LLC’s holdings in Perrigo were worth $826,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. State of Alaska Department of Revenue boosted its position in shares of Perrigo by 2.8% during the 1st quarter. State of Alaska Department of Revenue now owns 15,984 shares of the company’s stock valued at $448,000 after purchasing an additional 430 shares in the last quarter. Cedar Wealth Management LLC boosted its position in shares of Perrigo by 2.1% during the 4th quarter. Cedar Wealth Management LLC now owns 21,966 shares of the company’s stock valued at $565,000 after purchasing an additional 450 shares in the last quarter. Fox Run Management L.L.C. boosted its position in shares of Perrigo by 5.1% during the 4th quarter. Fox Run Management L.L.C. now owns 11,381 shares of the company’s stock valued at $293,000 after purchasing an additional 548 shares in the last quarter. Linden Thomas Advisory Services LLC boosted its position in shares of Perrigo by 3.8% during the 1st quarter. Linden Thomas Advisory Services LLC now owns 19,707 shares of the company’s stock valued at $553,000 after purchasing an additional 724 shares in the last quarter. Finally, Snowden Capital Advisors LLC boosted its position in shares of Perrigo by 3.6% during the 4th quarter. Snowden Capital Advisors LLC now owns 24,337 shares of the company’s stock valued at $626,000 after purchasing an additional 842 shares in the last quarter. Institutional investors own 95.91% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Perrigo from a “hold” rating to a “buy” rating in a research report on Saturday, July 5th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $33.00.

Perrigo Trading Down 1.3%

Shares of Perrigo stock opened at $27.04 on Wednesday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.28 and a current ratio of 2.36. Perrigo Company plc has a 52 week low of $23.14 and a 52 week high of $30.93. The stock has a 50 day moving average price of $26.80 and a two-hundred day moving average price of $26.10. The stock has a market capitalization of $3.72 billion, a PE ratio of -20.64 and a beta of 0.45.

Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.04. Perrigo had a positive return on equity of 8.93% and a negative net margin of 4.16%. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter last year, the firm posted $0.29 earnings per share. The company’s revenue for the quarter was down 3.5% compared to the same quarter last year. As a group, equities analysts anticipate that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 17th. Stockholders of record on Friday, May 30th were issued a $0.29 dividend. The ex-dividend date was Friday, May 30th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 4.29%. Perrigo’s dividend payout ratio is presently -88.55%.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.